IngenOx Therapeutics
http://cellerontherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From IngenOx Therapeutics
SynOx Seeks Solution For TGCT With Roche Antibody
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather
Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.
Enteric Fever, Plague Vaccines From Synthetic Biology Firm Near Clinical Studies
The oral administration of synthetic thermostable vaccines that use a bacterial vector could enter clinical studies in 2019, funded by VCs interested in their use in emerging markets, where endemic and childhood diseases could yield to the new approach.
Quintiles invests in biomarker start-up; Glyn Edwards to head
Quintiles has invested £3 million in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomarkers to clients.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Argonaut Therapeutics
- Celleron Therapeutics Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice